At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
parsaclisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
In Brief
A Phase 2 clinical trial evaluating parsaclisib for Lymphoma. Completed, enrolled 42 participants across 30 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartSep 2020
Primary CompletionFeb 2023
Study CompletionOct 2023
TodayJul 2026
First PostedJun 17, 2020
Enrollment StartSep 30, 2020
Primary CompletionFeb 16, 2023
Study CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.0 years ago
Interventions
parsaclisibdrug
parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits